Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | DRD3 | P35462 | 5/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | HRH2 | P25021 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15759107 | 0.82 | L3MBTL1 (0.50) | HSD11B1PDE3BPDE3APOLBHTR4 | |
| SCHEMBL11928135 | 0.81 | L3MBTL1 (0.57) | HSD11B1PDE3BPDE3AHTR4DRD3 | |
| SCHEMBL5605820 | 0.81 | HSD11B1 (0.47) | HSD11B1PDE3BPDE3APOLBHTR4 | |
| SCHEMBL11923486 | 0.80 | ATM (0.44) | HTR1AGLAATM | |
| SCHEMBL26511515 | 0.79 | GNAI3 (0.56) | HSD11B1HTR4HRH2HRH1 | |
| SCHEMBL11923454 | 0.78 | HSD11B1 (0.45) | HSD11B1PDE3BPDE3APOLBHTR4 | |
| SCHEMBL11908890 | 0.77 | ATM (0.44) | HTR7GLAATM | |
| SCHEMBL11410 | 0.75 | NPC1 (0.40) | DRD3DRD2GLA | |
| SCHEMBL12395531 | 0.75 | DRD3 (0.61) | HSD11B1PDE3BPDE3APOLBDRD3 | |
| SCHEMBL9029279 | 0.75 | HTR1A (0.43) | HSD11B1PDE3BPDE3AHTR4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118754-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-9834560-B2 | Compounds | RESPIVERT LTD. (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-20160264583-A1 | COMPOUNDS | RESPIVERT LTD. (GB) | 2016-09-15 | — | — | US | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-9321773-B2 | Compounds | Respivert, Ltd. (GB) | 2016-04-26 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-20140249164-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2014-09-04 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| US-8741909-B2 | PI3 kinase inhibitors | RESPIVERT LTD. (GB) | 2014-06-03 | — | — | US | disclosed |
| EP-2491037-B1 | QUINAZOLIN-4(3H)-ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-04-30 | — | — | EP | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120208799-A1 | COMPOUNDS | RESPIVERT LTD (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011048111-A1 | COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264583-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | HSD11B1 117/4885PDE3B 323/4885PDE3A 596/4885 |
| US-20140249164-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | HSD11B1 117/4885PDE3B 323/4885PDE3A 596/4885 |
| US-20120208799-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | HSD11B1 117/4885PDE3B 323/4885PDE3A 596/4885 |
| US-20180118754-A1 | COMPOUNDS | LTC4S, CYP11B2, LTB4R2 | HSD11B1 117/4885PDE3B 323/4885PDE3A 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.